Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33 3 20 16 40 00
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees148
Next Earnings DateN/A
OptionableNot Optionable
Genfit (OTCMKTS:GNFTF) Frequently Asked Questions
What is Genfit's stock symbol?
Genfit trades on the OTCMKTS under the ticker symbol "GNFTF."
What price target have analysts set for GNFTF?
2 equities research analysts have issued twelve-month price objectives for Genfit's shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate Genfit's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View Analyst Price Targets for Genfit.
What is the consensus analysts' recommendation for Genfit?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genfit.
Has Genfit been receiving favorable news coverage?
News coverage about GNFTF stock has trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genfit earned a news impact score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Genfit.
Who are some of Genfit's key competitors?
Some companies that are related to Genfit include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM) and China Longyi Group Int'l (CGYG).
What other stocks do shareholders of Genfit own?
Who are Genfit's key executives?
Genfit's management team includes the folowing people:
- Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
- Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
- Dr. Dean W. Hum, Chief Operating Officer (Age 57)
- Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
- Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)
How do I buy shares of Genfit?
Shares of GNFTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genfit's stock price today?
One share of GNFTF stock can currently be purchased for approximately $16.72.
What is Genfit's official website?
How can I contact Genfit?
The company can be reached via phone at 33 3 20 16 40 00.
MarketBeat Community Rating for Genfit (OTCMKTS GNFTF)
MarketBeat's community ratings are surveys of what our community members think about Genfit and other stocks. Vote "Outperform" if you believe GNFTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNFTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
